VR Logo

ReShape Lifesciences Inc. (RSLS) download report


Healthcare | Medical Devices & Equipment

ReShape Lifesciences Inc. (RSLS) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.

IPO Date: 15-Nov-2007

Pres, CEO & Director: Mr. Barton P. Bandy

Sr. VP of Fin. & CFO: Mr. Thomas Stankovich

Listing: NASDAQ: RSLS

Country: United States

Headquarters: San Clemente, CA

Website: https://www.reshapelifesciences.com

Key Facts

Market cap: $10.54 Mln

Revenue (TTM): $13.52 Mln

Earnings (TTM): $-65.27 Mln

Cash: $22.77 Mln

Total Debt: $0.53 Mln

Insider's Holding: 12.32%

Liquidity: Low

52 Week range: $0.55 - 6.25

Shares outstanding: 18,693,200

10 Years Aggregate:

  • CFO: $-193.75 Mln
  • EBITDA: $-392.24 Mln
  • Net Profit: $-396.97 Mln

Stock Performance

Time Period ReShape Lifesciences (RSLS) S&P BSE Sensex S&P Small-Cap 600
YTD-65.84-9.18-18.78
1 month-29.96-4.78-8.00
3 months-52.52-9.66-13.65
1 Year-88.790.81-17.19
3 Years2.1910.336.10
5 Years-59.2411.345.87
10 Years-33.7711.749.84
As on 01-Jul-2022
Year ReShape Lifesciences (RSLS) S&P Small-Cap 600 S&P BSE Sensex
2021-53.8025.2721.99
2020-38.269.5715.75
2019125.4920.8614.38
2018-82.60-9.705.87
2017-26.0011.7327.91
20161,437.2824.741.95
2015-90.84-3.36-5.03